Tregs protect the body from attack by T cells
Regulatory T cells (Tregs) suppress inflammation and keep T cells and other compartments of the immune system from attacking our own body.
Defective Tregs lead to autoimmune disease
Defective Tregs can no longer protect the body from the harmful effect of T cells, leading to autoimmune diseases including lupus, multiple sclerosis and rheumatoid arthritis, inflammatory disorders like Crohn's disease, and bone marrow failure syndromes like aplastic anemia.
A first-in-class, cord blood-derived Treg product
Clinically manufactured using Cellenkos' proprietary CRANE® platform from a single qualified umbilical cord blood unit, Cellenkos' Treg product shows superior T cell suppression and anti-inflammatory properties.
Infusion overcomes the existing Treg defect
Infusion of Cellenkos' Treg product replaces the defective Tregs and protects the body from T cell attack — releasing IL-10, consuming IL-2 that fuels aggressive T cells, and neutralizing antigen-presenting cells.
Restoring immune homeostasis
By preventing T cell attack against one's own body, Cellenkos' Treg product helps restore immune homeostasis — creating the conditions for disease control and tissue recovery.
